New drug classification: treatment with biological products class 1 new drug

Indications: used for solid tumor, the myeloid leukemia after chemotherapy in the treatment of thrombocytopenia

Project progress: transferred to the company in shandong, has approved the production

Project introduction: interleukin - 11, as a kind of cytokines have thrombopoiesis effect, it is mainly used for the prevention and treatment of solid tumor, the myeloid leukemia after concurrent chemoradiation thrombocytopenia, also used in the treatment of other causes of thrombocytopenia, can significantly reduce the incidence and severity of thrombocytopenia, reduce platelet transfusion.

Its mechanism is through direct stimulation of hematopoietic stem cells and huge nuclear progenitor cell proliferation, induction of megakaryocyte mature differentiation, promote the formation of platelet inside body, improve blood platelet count, effectively prevent because of reduced Numbers of platelets cause systemic disease.

Oncology: thrombocytopenia is one of the most common complication in patients with tumor radiation and chemotherapy, the clinical every 4 cases of radiation and chemotherapy patients meeting thrombocytopenia. Number of cancer each year about 1.6 million people in our country, the number of concurrent chemoradiation accounted for more than 1/2 around.

Onset: thrombocytopenia is malignancies are the main clinical symptoms. Leukemia is one of the top ten high incidence of malignant tumors in China, the leukemia patients in China is about 3-4 people / 100000 population, children with leukemia in malignant tumor incidence is highest. Studies have shown that interleukin - 11 can reduce platelet transfusion requirements leukemia patients.

In addition, interleukin - 11 can also be used for blood disease onset other thrombocytopenia, such as chronic aplastic anemia, idiopathic thrombocytopenic purpura, myelodysplastic syndrome, and so on.

Advantage: the clinical drugs to increase platelet only interleukin - 11 and platelet hormone (TPO). But TPO because of security concerns, suspended in a foreign country clinical trials, has not been approved. The interleukin - 11 still is the main drugs increase platelet, is also the only fda-approved drugs listed the ascension of platelets. A competitive market.